AR093740A1 - Amidas como inhibidores de pim - Google Patents

Amidas como inhibidores de pim

Info

Publication number
AR093740A1
AR093740A1 ARP130100648A ARP130100648A AR093740A1 AR 093740 A1 AR093740 A1 AR 093740A1 AR P130100648 A ARP130100648 A AR P130100648A AR P130100648 A ARP130100648 A AR P130100648A AR 093740 A1 AR093740 A1 AR 093740A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
alkyl
heterocyclyl
cycloalkyl
Prior art date
Application number
ARP130100648A
Other languages
English (en)
Inventor
Jr Chavez Frank
J Cee Victor
B Reed Anthony
L Smith Adrian
A Tamayo Nuria
Tasker Andrew
Wang Hui
Ling - Wu Bin
Wurz Ryan
Hu Harrington Essa
J Herberich Bradley
L M Jackson Claire
Alan Lanman Brian
H Norman Mark
T Nguyen Thomas
H Pettu Liping
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR093740A1 publication Critical patent/AR093740A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición farmacéutica y usos para la prevención y tratamiento del cáncer. Reivindicación 1: Un compuesto de la fórmula (1) en donde el enlace g es un enlace simple o un enlace doble; disponiéndose que g es un enlace simple si Y es C=O o C(Rᵃ)₂ o X es C=O o CH₂; el anillo a es un anillo que junto con los 2 átomos de carbono a los cuales se une, forma un anillo fenilo o un anillo heterocíclico de 5 - 6 miembros; X es N, NRᵇ, C=O, CH o CH₂; Y es N, NRᵇ, C=O, CRᵃ o C(Rᵃ)₂; R es una amida bicíclica opcionalmente sustituida, una tioamida bicíclica opcionalmente sustituida, una oxima bicíclica opcionalmente sustituida, o un compuesto del grupo de fórmulas (2); R¹ es H, halo, alquilo, amino, alquilamino, alquenilamino, haloalquilamino, alquilsulfonilalquilamino, aminocarbonilalquilamino, aminoalquilamino, hidroxialquilamino, alquilsulfonilamino, carboxialquilamino, alcoxicarbonilalquilamino, alcoxialquilamino, alcoxicarbonilaminoalquilamino, alcoxialcoxialquilamino, alcoxialquilaminoalquilamino, alquilsulfonilalquilaminoalquilamino, cicloalquilamino sustituido o no sustituido, cicloalquilalquilamino sustituido o no sustituido, arilamino sustituido o no sustituido, arilalquilamino sustituido o no sustituido, heterociclilamino sustituido o no sustituido, heterociclil-alquil C₁₋₆amino sustituido o no sustituido, guanidinilo, -CONHRᵇ, -NHC=ORᵇ, -ORᵇ, -S(=O)ₙRᵇ, -CORᶜ, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, arilalquenilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, cicloalquilalquilo sustituido o no sustituido, heterociclilalquilo sustituido o no sustituido o heterociclilo sustituido o no sustituido; R² es H, o halo; Rᵃ es H, halo, haloalquilo, hidroxialquilo, alquilo, alquinilalcoxi, amino, alquilamino, ciano, HC(=O)-, HC(=NOH)-, carboxi, alcoxicarbonilo, o heterociclilo sustituido o no sustituido; Rᵇ es H, alquilo, haloalquilo, aminoalquilo, alcoxialquilo, cicloalquilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido o heterociclilo sustituido o no sustituido; Rᶜ es H, alquilo, alcoxi, alcoxialquilo, cicloalquilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido o heterociclilo sustituido o no sustituido; Rʰ es alquilo; Rᵐ es H, alquilo, cicloalquilo o aminoalquilo; y una sal farmacéuticamente aceptable del mismo.
ARP130100648A 2012-02-28 2013-02-28 Amidas como inhibidores de pim AR093740A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261604444P 2012-02-28 2012-02-28
US201261720936P 2012-10-31 2012-10-31

Publications (1)

Publication Number Publication Date
AR093740A1 true AR093740A1 (es) 2015-06-24

Family

ID=47827485

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100648A AR093740A1 (es) 2012-02-28 2013-02-28 Amidas como inhibidores de pim

Country Status (5)

Country Link
US (1) US9394297B2 (es)
AR (1) AR093740A1 (es)
TW (1) TW201348226A (es)
UY (1) UY34648A (es)
WO (1) WO2013130660A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
MX2015009057A (es) 2013-01-15 2015-10-05 Incyte Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de cinasa pim.
WO2014165127A1 (en) * 2013-03-12 2014-10-09 Abbvie Inc. Pyrrole amide inhibitors
CA2918530C (en) 2013-07-19 2023-10-03 Onyx Therapeutics, Inc. Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers
TW201605866A (zh) 2013-08-23 2016-02-16 英塞特公司 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物
EP3035936B1 (en) * 2013-08-23 2019-03-13 NeuPharma, Inc. Certain chemical entities, compositions, and methods
FR3019819B1 (fr) * 2014-04-09 2018-03-23 Centre National De La Recherche Scientifique (Cnrs) Composes cytotoxiques inhibiteurs de la polymerisation de la tubuline
CN104262268B (zh) * 2014-07-10 2016-03-02 浙江工业大学 一种2-腈基喹喔啉类化合物的合成方法
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
TWI770525B (zh) 2014-12-30 2022-07-11 美商瓦洛健康公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
WO2016126926A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
JP2018504432A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのイソチアゾロピリミジノン、ピラゾロピリミジノン及びピロロピリミジノン
WO2016126929A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
CA2976227C (en) 2015-02-17 2023-10-24 Neupharma, Inc. Quinazoline derivatives and their use in treatment of cancer
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
CN107849046B (zh) * 2015-06-03 2020-06-12 常州捷凯医药科技有限公司 作为erk抑制剂的杂环化合物
CN106536522B (zh) * 2015-06-03 2020-08-28 捷思英达医药技术（上海）有限公司 用于治疗银屑病的杂环化合物
CN105418440B (zh) * 2015-07-24 2017-08-25 张家港吉慕特化工科技有限公司 一种由异丙胺合成2‑氨基‑2‑甲基‑1‑丙醇的方法
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
US10525047B2 (en) 2016-03-25 2020-01-07 University Of Maryland, Baltimore County PIM kinase inhibitors in combination with RNA splicing modulators/inhibitors for treatment of cancers
EP3484881B1 (en) 2016-07-14 2020-04-29 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds
EP3484894B1 (en) 2016-07-14 2020-08-19 Bristol-Myers Squibb Company Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as par4 inhibitors
KR102492715B1 (ko) 2016-07-14 2023-01-26 브리스톨-마이어스 스큅 컴퍼니 모노시클릭 헤테로아릴 치환된 화합물
CA3033370A1 (en) 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
US11040958B2 (en) 2017-02-17 2021-06-22 Wuhan Ll Science And Technology Development Co., Ltd. Triazole antimicrobial derivative, pharmaceutical composition and use thereof
TWI782056B (zh) * 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
MA52183A (fr) 2018-04-06 2021-02-17 H Lundbeck As Procédé de préparation de 2,2-diméthylpipérazine
KR20210034554A (ko) * 2018-07-23 2021-03-30 스미또모 가가꾸 가부시키가이샤 화합물 및 그 제조 방법
EP3846904B1 (en) 2018-09-07 2023-05-31 Merck Patent GmbH 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives
TW202028207A (zh) 2018-09-25 2020-08-01 美商英塞特公司 吡唑并嘧啶化合物及其用途
LT3873903T (lt) 2018-10-31 2024-05-10 Gilead Sciences, Inc. Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
TW202102505A (zh) * 2019-03-29 2021-01-16 大陸商江蘇恆瑞醫藥股份有限公司 吡咯并雜環類衍生物、其製備方法及其在醫藥上的應用
CN109824675A (zh) * 2019-04-09 2019-05-31 唐山师范学院 一种4-氯吡咯并嘧啶的合成方法
CN110078674B (zh) * 2019-04-10 2022-11-01 昆明理工大学 一种2-烃基胺基嘧啶酮的制备方法
EP3725788A1 (en) * 2019-04-15 2020-10-21 Bayer AG Novel heteroaryl-substituted aminoalkyl azole compounds as pesticides
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
AU2020288273A1 (en) * 2019-06-06 2022-01-06 Hutchison Medipharma Limited Tricyclic compounds and their use
CA3194077A1 (en) * 2020-09-29 2022-04-07 Xianqiang ZHOU Crystal form of pyrrolo heterocyclic derivative and preparation method therefor
CN114315837B (zh) * 2020-09-29 2023-06-16 江苏恒瑞医药股份有限公司 一种erk抑制剂的结晶形式及其制备方法
WO2023078401A1 (en) * 2021-11-05 2023-05-11 Fochon Biosciences, Ltd. Compounds as protein kinase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP1265897A1 (en) 2000-03-20 2002-12-18 Axys Pharmaceuticals, Inc. Non-amidine containing protease inhibitors
KR101616388B1 (ko) 2006-03-27 2016-04-29 네르비아노 메디칼 사이언시스 에스.알.엘. 키나제 억제제로서의 피리딜- 및 피리미디닐-치환된 피롤-, 티오펜- 및 푸란-유도체
EP2217601A1 (en) * 2007-11-08 2010-08-18 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyridazines for use as protein kinase inhibitors
CA2790176A1 (en) 2010-02-18 2011-08-25 Centro Nacional De Investigaciones Oncologicas (Cnio) Triazolo [4, 5 - b] pyridin derivatives
EP2649065A1 (en) 2010-12-09 2013-10-16 Amgen Inc. Bicyclic compounds as pim inhibitors
JP2014510105A (ja) * 2011-03-22 2014-04-24 アムジエン・インコーポレーテツド Ｐｉｍ阻害剤としてのアゾール化合物

Also Published As

Publication number Publication date
US9394297B2 (en) 2016-07-19
WO2013130660A1 (en) 2013-09-06
US20150329538A1 (en) 2015-11-19
TW201348226A (zh) 2013-12-01
UY34648A (es) 2013-09-02

Similar Documents

Publication Publication Date Title
AR093740A1 (es) Amidas como inhibidores de pim
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
EA201790108A1 (ru) Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201892740A2 (ru) Полифторзамещенное соединение в качестве ингибитора тирозинкиназы брутона (btk)
NZ703064A (en) Inhibitors of hepatitis c virus
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
BR112015018509A2 (pt) compostos de imidazo piridina
AR073551A1 (es) Pirimidinas macrociclicas como inhibidores de proteina cinasa
EA202090052A1 (ru) Содержащие имидазол ингибиторы alk2 киназы
EA201492170A1 (ru) Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
EA201791816A1 (ru) Ингибиторы kv1.3 и их применение в медицине
AR081893A1 (es) Derivados de acido 1-(2-fluorobifenil-4-il)-alquil carboxilico para la terapia de la amiloidosis transtiretina
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
MX2013007892A (es) Derivados de fenetilsulfona isoindolina y su uso.
AR080228A1 (es) Derivados de piridina triciclicos medicamentos que contienen tales compuestos su uso y proceso para su preparacion

Legal Events

Date Code Title Description
FB Suspension of granting procedure